Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pfizer Inc. is conducting an open-label Phase 1 clinical trial titled AN OPEN-LABEL PHASE 1 STUDY TO EVALUATE PF-08046037 AS MONOTHERAPY AND PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED MALIGNANCIES. The study aims to assess the safety and effects of PF-08046037, alone or combined with sasanlimab, in patients with advanced or metastatic malignancies, including non-small cell lung cancer, head and neck squamous cell carcinoma, melanoma, and pancreatic ductal adenocarcinoma. This study is significant as it explores potential new treatments for these challenging cancer types.
The interventions being tested are PF-08046037, administered intravenously, and sasanlimab, given subcutaneously. The study seeks to determine the optimal dosing and safety profile of these drugs, either as monotherapy or in combination.
The study design is interventional and non-randomized, following a sequential intervention model with dose escalation and expansion phases. It is unmasked, meaning all participants and researchers know which treatments are being administered. The primary purpose is treatment-focused, aiming to find effective doses and assess safety.
The study began on May 6, 2025, with the primary completion and estimated completion dates yet to be announced. The last update was submitted on August 14, 2025. These dates are crucial for tracking the study’s progress and anticipating results that could impact market dynamics.
Pfizer’s ongoing study could influence its stock performance positively if the results show promising efficacy and safety, enhancing investor confidence. This development is particularly relevant in the competitive oncology market, where advancements can significantly shift market positions.
The study is currently recruiting, with further details available on the ClinicalTrials portal.